Secretory carcinoma of the major salivary gland: a provincial population-based analysis of clinical behavior and outcomes

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11140%2F19%3A10386657" target="_blank" >RIV/00216208:11140/19:10386657 - isvavai.cz</a>

Výsledek na webu

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kWNwQat4tF" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=kWNwQat4tF</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1002/hed.25536" target="_blank" >10.1002/hed.25536</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Secretory carcinoma of the major salivary gland: a provincial population-based analysis of clinical behavior and outcomes

Popis výsledku v původním jazyce

Secretory carcinoma (SC) of the salivary gland, previouslyknown as mammary analog SC, is a recently described tumor, occurring principally in the salivary glands, which resembles SC of the breast and includes a characteristic ETV6 gene rearrangement.1 SC may be distinguished from similar tumors such as acinic cell carcinoma, low-grade intraductal carcinoma, and adenocarcinoma, not otherwise specified (NOS) by few or absent zymogen granules or increased extracellular mucin and by immunohistochemical (IHC) positivity for S-100 protein and mammaglobin.1-6 The diagnosis is confirmed by molecular testing for ETV6 rearrangement by fluorescent in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RTPCR).1-3,5,7,8 The most common reported reciprocal translocation is t(12;15) (p13;q25), which leads to fusion of the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15 although other ETV6 translocation partners have been described.9,10 The resulting ETV6 fusion protein has shown transforming activity in several cell lines11 and has been described in a variety of tumors including secretory breast carcinoma,12 infantile fibrosarcoma,13 congenital mesoblastic nephroma,14,15 and radiation-induced thyroid cancer.16 There are now over 200 published cases of SC since the original description by Skálová in 20101; however, most studi s have reevaluated historical files only of acinic cell carcinoma and other mimickers of SC.5,6,8 Although the histopathology, IHC, and cytology of SC are well characterized, relatively few studies have addressed its clinical behavior with long-term follow-up.1-3,6,7,10,17,18 We present a review of the clinical behavior of cases identified through systematic retrospective review of all malignant salivary gland tumors (MSGTs) presenting to a large provincial health care system.

Název v anglickém jazyce

Secretory carcinoma of the major salivary gland: a provincial population-based analysis of clinical behavior and outcomes

Popis výsledku anglicky

Secretory carcinoma (SC) of the salivary gland, previouslyknown as mammary analog SC, is a recently described tumor, occurring principally in the salivary glands, which resembles SC of the breast and includes a characteristic ETV6 gene rearrangement.1 SC may be distinguished from similar tumors such as acinic cell carcinoma, low-grade intraductal carcinoma, and adenocarcinoma, not otherwise specified (NOS) by few or absent zymogen granules or increased extracellular mucin and by immunohistochemical (IHC) positivity for S-100 protein and mammaglobin.1-6 The diagnosis is confirmed by molecular testing for ETV6 rearrangement by fluorescent in situ hybridization (FISH) or reverse transcription polymerase chain reaction (RTPCR).1-3,5,7,8 The most common reported reciprocal translocation is t(12;15) (p13;q25), which leads to fusion of the ETV6 gene on chromosome 12 and the NTRK3 gene on chromosome 15 although other ETV6 translocation partners have been described.9,10 The resulting ETV6 fusion protein has shown transforming activity in several cell lines11 and has been described in a variety of tumors including secretory breast carcinoma,12 infantile fibrosarcoma,13 congenital mesoblastic nephroma,14,15 and radiation-induced thyroid cancer.16 There are now over 200 published cases of SC since the original description by Skálová in 20101; however, most studi s have reevaluated historical files only of acinic cell carcinoma and other mimickers of SC.5,6,8 Although the histopathology, IHC, and cytology of SC are well characterized, relatively few studies have addressed its clinical behavior with long-term follow-up.1-3,6,7,10,17,18 We present a review of the clinical behavior of cases identified through systematic retrospective review of all malignant salivary gland tumors (MSGTs) presenting to a large provincial health care system.

Druh

J_imp - Článek v periodiku v databázi Web of Science

CEP obor

—

OECD FORD obor

30109 - Pathology

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2019

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Head &amp; Neck

ISSN

1043-3074

e-ISSN

—

Svazek periodika

41

Číslo periodika v rámci svazku

5

Stát vydavatele periodika

US - Spojené státy americké

Počet stran výsledku

10

Strana od-do

1227-1236

Kód UT WoS článku

000466490000015

EID výsledku v databázi Scopus

2-s2.0-85059274296